Latanoprost is a cornerstone medication in the management of open-angle glaucoma and ocular hypertension. Its complex molecular structure necessitates the use of specific, high-quality intermediates during its synthesis. Among these, 1-Bromo-4-phenyl-2-butanone (CAS 31984-10-8) plays a pivotal role, serving as a key precursor that enables efficient and cost-effective manufacturing.

The chemical properties of 1-Bromo-4-phenyl-2-butanone, particularly its reactive bromine atom and ketone functional group, make it an ideal starting material for constructing the prostaglandin backbone of Latanoprost. Its typical appearance as a white crystalline powder with an assay of ≥98.0% ensures the precision required in multi-step pharmaceutical synthesis. For R&D scientists and manufacturing teams, securing a consistent supply of this intermediate is critical for maintaining production continuity and product integrity.

When considering the purchase of 1-Bromo-4-phenyl-2-butanone, partnering with a reliable chemical manufacturer, especially those based in China with strong expertise in fine chemicals, is a strategic advantage. These suppliers often offer not only competitive pricing but also a commitment to quality that is essential for pharmaceutical applications. Looking for manufacturers that provide detailed technical data, including CoA and batch-to-batch consistency, is paramount.

The global demand for Latanoprost means that the supply chain for its key intermediates must be robust and dependable. As a dedicated manufacturer of pharmaceutical building blocks, we understand the importance of reliable supply. By choosing to buy from established suppliers, companies can mitigate risks associated with quality variations and potential shortages, thereby ensuring that patient access to essential medications is not compromised.

In summary, the efficient synthesis of Latanoprost is significantly influenced by the availability and quality of 1-Bromo-4-phenyl-2-butanone. Pharmaceutical procurement specialists and chemists should prioritize sourcing this critical intermediate from trusted manufacturers who can guarantee purity, consistent quality, and a stable supply, thereby optimizing production and contributing to global healthcare.